Effectiveness of low-dose intradermal hepatitis B vaccination. Five years' experience of primary vaccination

S. C. Thompson; R. Darlington; D. Tallent; R. Robins-Browne; J. R L Forsyth

Effectiveness of low-dose intradermal hepatitis B vaccination. Five years' experience of primary vaccination

S. C. Thompson, R. Darlington, D. Tallent, R. Robins-Browne, J. R L Forsyth

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: To determine whether intradermal hepatitis B vaccination is an effective procedure. Design: A study of antibody responses to hepatitis B vaccine in 753 medical students. Setting: Routine vaccination of medical students with intradermal doses of hepatitis B vaccines of various origins. Outcome measures: Rates of seroconversion and geometric mean levels of antibody achieved. Results: Seroconversion rates, indicated by antibody to hepatitis B surface antigen (anti-HBs) levels of 10 mIU/mL or more, varied between 82% and 94.7% with different preparations of the vaccine. With a four-dose intradermal schedule over two successive cohorts, Engerix-B (SmithKline Beecham) gave better responses, in this context, than H-B-Vax II (Merck Sharp and Dohme). Any reactions to the vaccination were mild and local. Conclusion: The intradermal route is a practical method of vaccination against hepatitis B in healthy young adults when the cost of the vaccine is an inhibiting factor.

Original language	English
Pages (from-to)	372-375
Number of pages	4
Journal	Medical Journal of Australia
Volume	158
Issue number	6
Publication status	Published - 1 Jan 1993

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{fc28531f99ba4f8e98985b9d00b5622b,

title = "Effectiveness of low-dose intradermal hepatitis B vaccination. Five years' experience of primary vaccination",

abstract = "Objective: To determine whether intradermal hepatitis B vaccination is an effective procedure. Design: A study of antibody responses to hepatitis B vaccine in 753 medical students. Setting: Routine vaccination of medical students with intradermal doses of hepatitis B vaccines of various origins. Outcome measures: Rates of seroconversion and geometric mean levels of antibody achieved. Results: Seroconversion rates, indicated by antibody to hepatitis B surface antigen (anti-HBs) levels of 10 mIU/mL or more, varied between 82% and 94.7% with different preparations of the vaccine. With a four-dose intradermal schedule over two successive cohorts, Engerix-B (SmithKline Beecham) gave better responses, in this context, than H-B-Vax II (Merck Sharp and Dohme). Any reactions to the vaccination were mild and local. Conclusion: The intradermal route is a practical method of vaccination against hepatitis B in healthy young adults when the cost of the vaccine is an inhibiting factor.",

author = "Thompson, {S. C.} and R. Darlington and D. Tallent and R. Robins-Browne and Forsyth, {J. R L}",

year = "1993",

month = jan,

day = "1",

language = "English",

volume = "158",

pages = "372--375",

journal = "Medical Journal of Australia",

issn = "0025-729X",

publisher = "Australasian Medical Publishing Co. Ltd",

number = "6",

}

TY - JOUR

T1 - Effectiveness of low-dose intradermal hepatitis B vaccination. Five years' experience of primary vaccination

AU - Thompson, S. C.

AU - Darlington, R.

AU - Tallent, D.

AU - Robins-Browne, R.

AU - Forsyth, J. R L

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Objective: To determine whether intradermal hepatitis B vaccination is an effective procedure. Design: A study of antibody responses to hepatitis B vaccine in 753 medical students. Setting: Routine vaccination of medical students with intradermal doses of hepatitis B vaccines of various origins. Outcome measures: Rates of seroconversion and geometric mean levels of antibody achieved. Results: Seroconversion rates, indicated by antibody to hepatitis B surface antigen (anti-HBs) levels of 10 mIU/mL or more, varied between 82% and 94.7% with different preparations of the vaccine. With a four-dose intradermal schedule over two successive cohorts, Engerix-B (SmithKline Beecham) gave better responses, in this context, than H-B-Vax II (Merck Sharp and Dohme). Any reactions to the vaccination were mild and local. Conclusion: The intradermal route is a practical method of vaccination against hepatitis B in healthy young adults when the cost of the vaccine is an inhibiting factor.

AB - Objective: To determine whether intradermal hepatitis B vaccination is an effective procedure. Design: A study of antibody responses to hepatitis B vaccine in 753 medical students. Setting: Routine vaccination of medical students with intradermal doses of hepatitis B vaccines of various origins. Outcome measures: Rates of seroconversion and geometric mean levels of antibody achieved. Results: Seroconversion rates, indicated by antibody to hepatitis B surface antigen (anti-HBs) levels of 10 mIU/mL or more, varied between 82% and 94.7% with different preparations of the vaccine. With a four-dose intradermal schedule over two successive cohorts, Engerix-B (SmithKline Beecham) gave better responses, in this context, than H-B-Vax II (Merck Sharp and Dohme). Any reactions to the vaccination were mild and local. Conclusion: The intradermal route is a practical method of vaccination against hepatitis B in healthy young adults when the cost of the vaccine is an inhibiting factor.

UR - http://www.scopus.com/inward/record.url?scp=0027522855&partnerID=8YFLogxK

M3 - Article

C2 - 8479349

AN - SCOPUS:0027522855

SN - 0025-729X

VL - 158

SP - 372

EP - 375

JO - Medical Journal of Australia

JF - Medical Journal of Australia

IS - 6

ER -

Effectiveness of low-dose intradermal hepatitis B vaccination. Five years' experience of primary vaccination

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this